MyFinsight
Home
Blog
About
Contact
Download
Download image
Nuvaxovid Sales
$625,182K
Supply Sales
$59,859K
Product
$685,041K
Licensing Royalties And
Other
$438,438K
Revenues
$1,123,479K
(64.69%↑ Y/Y)
Income (loss) from
operations
$452,795K
(281.90%↑ Y/Y)
Other income, net
$40,633K
(0.47%↑ Y/Y)
Total expenses
$670,684K
(-27.97%↓ Y/Y)
Income (loss) before
income tax expense
$442,167K
(350.36%↑ Y/Y)
Loss on debt
extinguishment
-$28,714K
Interest expense
$22,547K
(12.31%↑ Y/Y)
Research and development
$342,320K
(-12.49%↓ Y/Y)
Selling, general, and
administrative
$157,479K
(-53.30%↓ Y/Y)
Impairment of assets held
for sale
$97,845K
Cost of sales
$73,040K
(-63.97%↓ Y/Y)
Net income (loss)
$440,302K
(334.83%↑ Y/Y)
Income tax expense
$1,865K
(-82.86%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)